Meghna Samant

1.5k total citations
28 papers, 1.1k citations indexed

About

Meghna Samant is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Meghna Samant has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Meghna Samant's work include HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Meghna Samant is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Meghna Samant collaborates with scholars based in United States, Switzerland and France. Meghna Samant's co-authors include Jens Huober, Véronique Dièras, Ian E. Krop, Ellie Guardino, Nancy U. Lin, Kimberly Blackwell, Manfred Welslau, Mengdi Lu, David Miles and Alice E. Guardino and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Meghna Samant

28 papers receiving 1.1k citations

Peers

Countries citing papers authored by Meghna Samant

Since Specialization

Citations

This map shows the geographic impact of Meghna Samant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meghna Samant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meghna Samant more than expected).

Fields of papers citing papers by Meghna Samant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meghna Samant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meghna Samant. The network helps show where Meghna Samant may publish in the future.

Co-authorship network of co-authors of Meghna Samant

This figure shows the co-authorship network connecting the top 25 collaborators of Meghna Samant. A scholar is included among the top collaborators of Meghna Samant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meghna Samant. Meghna Samant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Emily Castellanos, Joseph Fiore, Stephen J. Lane, (unknown), (unknown), Venkat Sethuraman, Meghna Samant, Ram C. Tiwari	6
2	Considerations for pooling real-world data as a comparator cohort to a single arm trial: a simulation study on assessment of heterogeneity 2023 ·BMC Medical Research Methodology ·Daniel Backenroth, Trevor J. Royce, José Cirı́aco Pinheiro, Meghna Samant, Olivier Humblet	5
3	A systematic approach towards missing lab data in electronic health records: A case study in non‐small cell lung cancer and multiple myeloma 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Janick Weberpals, (unknown), Chengsheng Jiang, Michael D. Taylor, Meghna Samant, Sarah T. Cherng	5
4	Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations 2022 ·Contemporary Clinical Trials Communications ·(unknown), (unknown), Melissa D. Curtis, Shrujal S. Baxi, William B. Capra, Elizabeth Garrett‐Mayer, Brian P. Hobbs, David S. Hong, Rebecca A. Hubbard, Jiawen Zhu, Somnath Sarkar, Meghna Samant	10
5	PCN198 Statistical Methods for Pantumor Analysis: Models to Account for Tumor-Level Heterogeneity 2021 ·Value in Health ·Akshay Swaminathan, Jeremy Snider, (unknown), Meghna Samant, Olivier Humblet	1
6	Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC 2021 ·Advances in Therapy ·Xinran Ma, (unknown), (unknown), Caroline S. Bennette, Olga Tymejczyk, Meghna Samant, Melisa Tucker, Nathan C. Nussbaum, Bryan Bowser, (unknown), Ariel B. Bourla	30
7	Small But Mighty: The Use of Real‐World Evidence to Inform Precision Medicine 2019 ·Clinical Pharmacology & Therapeutics ·Rebecca A. Miksad, Meghna Samant, Somnath Sarkar, Amy P. Abernethy	19
8	Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane 2017 ·Cancer Chemotherapy and Pharmacology ·Chunze Li, Bei Wang, (unknown), Russell Wada, Dan Lu, Xin Wang, (unknown), Jonathan French, Shweta Vadhavkar, Alexander Strasak, Melanie C. Smitt, Amita Joshi, Meghna Samant, Angelica Quartino, Jin Jin, Sandhya Girish	23
9	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram	150
10	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA 2014 ·Annals of Oncology ·Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras	286
11	Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis 2014 ·Journal of Clinical Oncology ·Véronique Dièras, Nadia Harbeck, G. Thomas Budd, Joel K. Greenson, Alice E. Guardino, Meghna Samant, (unknown), Melanie C. Smitt, Ian E. Krop	91
12	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates 2014 ·Cancer Chemotherapy and Pharmacology ·Dan Lu, Sandhya Girish, Yuying Gao, Bei Wang, (unknown), Ellie Guardino, Meghna Samant, Melody Cobleigh, Mothaffar F. Rimawi, Pierfranco Conté, Jin Y. Jin	63
13	Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates 2012 ·Cancer Research ·Dongrui R. Lu, Sandhya Girish, Yue Gao, (unknown), (unknown), Ellie Guardino, Meghna Samant, Melody Cobleigh, (unknown), Pierfranco Conté, (unknown)	2
14	Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. 2012 ·Journal of Clinical Oncology ·Shanu Modi, Anthony Elias, Patricia LoRusso, Meghna Samant, Ellie Guardino, Betsy Althaus, Ian E. Krop	5
15	Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Mark A. Socinski, Frank A. Scappaticci, Meghna Samant, Margaret Kolb, Mark Kozloff	34
16	Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab 2010 ·Neuro-Oncology ·Michael Prados, Timothy F. Cloughesy, Meghna Samant, Fang Ting Liang, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W.K. Alfred Yung, Nina A. Paleologos, M. Kelly Nicholas, (unknown), James J. Vredenburgh, Asha Das, Henry S. Friedman	61
17	SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer 2010 ·Annals of Oncology ·(unknown), (unknown), Taral Patel, (unknown), C. J. Fabian, Mark Kozloff, (unknown), Fabio Volterra, Hema Parmar, Meghna Samant, Harold J. Burstein	37
18	Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study 2010 ·The Oncologist ·James J. Vredenburgh, Timothy F. Cloughesy, Meghna Samant, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W.K. Alfred Yung, Nina A. Paleologos, M. Kelly Nicholas, Randy L. Jensen, Asha Das, Henry S. Friedman	91
19	8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study 2009 ·European Journal of Cancer Supplements ·Michael D. Prados, Timothy F. Cloughesy, Meghna Samant, Fang Ting Liang, Arighno Das, Howard S. Frıedman	2
20	Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab 2009 ·Journal of Clinical Oncology ·Alan B. Sandler, Joan H. Schiller, Robert J. Gray, Isaiah W. Dimery, Julie R. Brahmer, Meghna Samant, Lisa I. Wang, David H. Johnson	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact